All In Biotech

Drug Trial Radar · NCT04470050

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on Opioids

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Jun 9, 2020

Primary completion

Feb 18, 2021

Study completion Feb 18, 2021

Sponsor

Lead sponsor
BioXcel Therapeutics IncIndustry
Sponsor type
Industry
Collaborators
Cognitive Research Corporation
First posted
Jul 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance. The opioid (morphine) maintenance phase (Phase 1b) included Days 1-5; the randomized BXCL501/placebo phase (Phase 2) included Days 6-12. The randomized phase was followed by 2 sequential days, Days 13 and 14, utilizing treatment of BXCL501-placebo sublingual films and morphine-placebo capsules for all subjects who remained in the study.

Conditions

  • Opioid Withdrawal

Interventions

  • DexmedetomidineDrug

    Sublingual Film of Dexmedetomidine

  • PlaceboDrug

    Sublingual Placebo film

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak SOWS Scores at Baseline and Over TimeTime frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • BioXcel Clinical Research Site

    Miami Lakes, Florida

  • BioXcel Clinical Research Site

    Marlton, New Jersey

  • BioXcel Clinical Research Site

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.